- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02174952
Self-help in Adjunct to Pharmacotherapy (SHIP)
June 24, 2014 updated by: University of Nottingham
Efficacy of a Self-help Parenting Intervention for Parents of Children With ADHD in Adjunct to Pharmacotherapy
Therapist-led parenting interventions have been shown to reduce symptoms of attention deficit hyperactivity disorder (ADHD) and are recommended as a first line treatment for school age children with ADHD.
However, parenting interventions can be costly and impractical for parents due to factors such as time constraints and travelling costs.
A self-help parent training manual has been developed and initial results have shown moderate reductions in ADHD symptoms, indicating that whilst self-help may offer a cost effective alternative to therapist led parent training interventions, it may not be sufficient to treat ADHD alone.
This study therefore aims to compare the efficacy and additional benefits of the self-help intervention plus treatment as usual including pharmacotherapy with a control treatment as usual group .
Families with a child aged 6-10 with a clinical diagnosis of ADHD will be recruited to the study via referrals from community paediatricians and child and adolescent mental health services.
After gaining informed consent subjects will be randomised to self-help plus Treatment as usual (TAU) + or TAU (control).
Those allocated to TAU+SH will be issued with the self-help manual and an introductory DVD to highlight key aspects of the intervention.
Self-help intervention will last for 12 weeks.
Data will be collected via standardised questionnaires completed by the parent, teacher and child and a recorded speech samples from the parent.
Data will be collected at three time points; pre-intervention, post-intervention (12 weeks) and as a long term follow up (28 weeks).
After completing the trial, qualitative data will be collected about participants' experience of self-help intervention.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Parent/Main caregiver aged 18 years or over.
- Children aged been 6-10 years who have received a clinical diagnosis of ADHD.
- Children who are about to commence a course of medication for ADHD for the first time or a currently receiving medication for ADHD.
Exclusion Criteria:
- Parents who are not fluent in English, or unable to read English. (Due to copyright restrictions the self-help manual is only available in English.)
- Families who clinicians feel may be unable/incapable of completing the self-help intervention (e.g. where parents have severe mental illness)
- Parents who are aware that they have had previous experience of the NFPP
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAU+SH
Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician.
They will also receive an introductory DVD aimed at highlighting key components of the intervention.
|
|
No Intervention: TAU
Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase.
Families in the TAU condition will be offered the self-help manual at the end of the trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy subscale of the Parenting Sense of Competence Questionnaire (PSOC)
Time Frame: Post- Intervention (12 weeks)
|
This questionnaire provides a measure of parenting confidence and satisfaction within their parenting role; parents of children with ADHD often report low parenting efficacy.
|
Post- Intervention (12 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child ADHD Symptoms
Time Frame: 12 weeks
|
Parent and teacher report according to SNAP-IV
|
12 weeks
|
Family Strain Index (Riley et al, 2006).
Time Frame: 12 weeks
|
12 weeks
|
|
Eyberg Child Behaviour Inventory (ECBI; Eyberg, 1980)
Time Frame: 12 weeks
|
12 weeks
|
|
Vanderbilt Diagnostic Rating Scale (Performance scale; Wolraich et al, 2003)
Time Frame: 12 weeks
|
12 weeks
|
|
Southampton ADHD medication behaviour and and Attitudes scale (SAMBA)
Time Frame: 12 weeks
|
12 weeks
|
|
Child Health and Illness Profile (parent and child report; Riley et al, 2004)
Time Frame: 12 weeks
|
12 weeks
|
|
Parental Expressed emotion via recorded Five Minute Speech Sample (Daley et al, 2003)
Time Frame: 12 weeks
|
12 weeks
|
|
General Health Questionnaire (12 item; Goldberg, 1992)
Time Frame: 12 weeks
|
12 weeks
|
|
Child ADHD symptoms
Time Frame: 28 weeks
|
Parent and teacher report according to SNAP-IV
|
28 weeks
|
Family Strain Index (Riley et al, 2006)
Time Frame: 28 weeks
|
28 weeks
|
|
Eyberg Child Behaviour Inventory (ECBI; Eyberg, 1980)
Time Frame: 28 weeks
|
28 weeks
|
|
Vanderbilt Diagnostic Rating Scale (Performance scale; Wolraich et al, 2003)
Time Frame: 28 weeks
|
28 weeks
|
|
Southampton ADHD medication behaviour and and Attitudes scale (SAMBA)
Time Frame: 28 weeks
|
28 weeks
|
|
Child Health and Illness Profile (parent and child report; Riley et al, 2004)
Time Frame: 28 weeks
|
28 weeks
|
|
General Health Questionnaire (12 item; Goldberg, 1992)
Time Frame: 28 weeks
|
28 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Fidelity
Time Frame: Fortnightly throughout intervention period
|
Fidelity of self-help intervention will be assessed using a parent self-report rating collected via fortnightly phone calls to parents from research/clinic staff.
|
Fortnightly throughout intervention period
|
Usual Treatment
Time Frame: Baseline, Post-intervention (12 weeks) follow-up (28 weeks)
|
A treatment report form questionnaire will be used to gain information about other treatments being received for ADHD.
This information will be requested initially from parents and then, with consent, from clinicians if parents feel unable/fail to provide.
|
Baseline, Post-intervention (12 weeks) follow-up (28 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Anticipated)
September 1, 2014
Study Completion (Anticipated)
September 1, 2014
Study Registration Dates
First Submitted
June 23, 2014
First Submitted That Met QC Criteria
June 24, 2014
First Posted (Estimate)
June 26, 2014
Study Record Updates
Last Update Posted (Estimate)
June 26, 2014
Last Update Submitted That Met QC Criteria
June 24, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12031
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder (ADHD)
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention-Deficit Hyperactivity Disorder (ADHD)United States
-
Massachusetts General HospitalShireCompletedAttention Deficit/Hyperactivity Disorder(ADHD)United States
-
Medical University of South CarolinaShireCompletedAdult Attention Deficit Hyperactivity Disorder (ADHD)United States
-
Sheba Medical CenterCompletedADHD Predominantly Inattentive Type | Attention Deficit/Hyperactivity Disorder Combined Type | ADHD Predominantly Hyperactivity Type | ADHD-not Other SpecifiedIsrael
-
Cingulate TherapeuticsRho, Inc.CompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder CombinedUnited States
-
Tris Pharma, Inc.Massachusetts General Hospital; Massachusetts Institute of TechnologyCompleted
-
Karolinska InstitutetRegion StockholmCompleted
Clinical Trials on Self-help version of the New Forest Parenting Programme
-
University of AarhusGlostrup University Hospital, Copenhagen; TrygFonden, Denmark; Sygekassernes...CompletedAttention Deficit Hyperactivity DisorderDenmark
-
McMaster UniversityCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); Florida Department of HealthCompleted
-
University Hospital, LilleNational Research Agency, FranceCompleted
-
Kaiser PermanenteNational Institute of Mental Health (NIMH)Unknown
-
St. Martin De Porress HospitalRecruiting
-
World BankAddis Ababa University; Ethiopian Medical Association; Policy Studies InstituteRecruitingStress | Emotion Regulation | Mental Stress | Violence, Gender-Based | Stress, Job | Economic ProblemsEthiopia
-
Parc de Salut MarResearch Institute for Public Health and Addiction, SwitzerlandRecruiting
-
University of BernCompletedDepression Moderate | Depression MildSwitzerland
-
University of Ljubljana, Faculty of MedicineUniversity Medical Centre Ljubljana; University Maribor; University Psychiatric...RecruitingNon-Suicidal Self Injury | Self-harm | Personality Disorder, Borderline | Difference, Individual | Epigenetic Disorder | Change; MentalSlovenia